CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 1,150 enrolled
Drug / intervention
Remifentanil group +1 moredrug
Likely dose
Remifentanil group 4µgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03960801
NCT03960801Phase 3Completed
CompareCT.gov

Assessment of Remifentanil for Rapid Sequence Induction and Intubation in Full Stomach Patient Compared to Muscle Relaxant. A Non-inferiority Simple Blind Randomized Controlled Trial

Nantes University Hospital·interventional·Posted May 23, 2019·Updated Apr 27, 2021

In Brief

A Phase 3 clinical trial evaluating Remifentanil group and neuromuscular blockade group for Intra-tracheal Intubation. Completed, enrolled 1,150 participants across 13 sites.

Detailed Summary

REMICrush is a French multicentric non inferiority simple blind randomized clinical trial that will compare the use of Remifentanil to muscle relaxant (reference treatment) for anesthetic rapid sequence intubation in terms of major complications (difficult intubation, gastric liquid aspiration, desaturation, hemodynamics reaction, ventricular arrhythmia, anaphylactic reaction).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIntra-tracheal Intubation
CountriesFrance
Collaborators--

Timeline

Phase 3CompletedFinished
2020202120222023202420252026
First PostedMay 23, 2019
Enrollment StartOct 9, 2019
Primary CompletionApr 22, 2021
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 7.1 years ago

Interventions

Remifentanil groupdrug

bolus intravenous injection of 3 to 4µg/kg of remifentanil after hypnotic administration for a crush anesthetic induction

neuromuscular blockade groupdrug

Bolus intravenous injection of 1mg/kg of Succinylcholine or Rocuronium after hypnotic administration for a crush anesthetic induction